A New Era in Alzheimer’s Research
There’s a lot at stake for Alzheimer’s research and development. Importantly the first product to market which claims disease-modifying properties will dominate potentially pharma’s largest product sector for several years. In the quest for disease and related disorders, many different theories have emerged to explain the underlying processes. Liz Moench at MediciGlobal and Professor Claude Wischik at TauRx Therapeutics look at two main pathological features found in the brains of Alzheimer’s patients.